Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients
M. Mimpen,
D. Kreiter,
T. Kempkens,
S. Knippenberg,
R. Hupperts,
O. Gerlach
Affiliations
M. Mimpen
Academic MS Center Zuyderland, Zuyderland Medical Center Sittard-Geleen, the Netherlands; School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
D. Kreiter
Academic MS Center Zuyderland, Zuyderland Medical Center Sittard-Geleen, the Netherlands; School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands; Corresponding author.
T. Kempkens
Academic MS Center Zuyderland, Zuyderland Medical Center Sittard-Geleen, the Netherlands
S. Knippenberg
Academic MS Center Zuyderland, Zuyderland Medical Center Sittard-Geleen, the Netherlands
R. Hupperts
Academic MS Center Zuyderland, Zuyderland Medical Center Sittard-Geleen, the Netherlands; School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
O. Gerlach
Academic MS Center Zuyderland, Zuyderland Medical Center Sittard-Geleen, the Netherlands; School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
Multiple sclerosis immunomodulatory treatments such as cladribine, which affects both B- and T-lymphocytes, can potentially alter the humoral response to SARS-CoV-2 vaccination. This monocenter retrospective study reports on anti-SARS-CoV-2 IgG antibody response in cladribine treated MS patients and we compare the response in patients vaccinated before and after an 18-week interval after last cladribine dose. Of the 34 patients (5 patients ≤ 18 weeks and 29 patients > 18 weeks after last cladribine dose) that were included, 32 reached seropositivity (94 %). All patients vaccinated < 18 weeks after last cladribine dose reached seropositivity. This study confirms findings of earlier reports that cladribine-treated MS patients show an adequate humoral response after SARS-CoV-2 vaccination, even when vaccinated early (≤18 weeks) after last cladribine dose.
